» Articles » PMID: 22754527

The Effects of Psychostimulant Drugs on Blood Brain Barrier Function and Neuroinflammation

Overview
Journal Front Pharmacol
Date 2012 Jul 4
PMID 22754527
Citations 95
Authors
Affiliations
Soon will be listed here.
Abstract

The blood brain barrier (BBB) is a highly dynamic interface between the central nervous system (CNS) and periphery. The BBB is comprised of a number of components and is part of the larger neuro(glio)vascular unit. Current literature suggests that psychostimulant drugs of abuse alter the function of the BBB which likely contributes to the neurotoxicities associated with these drugs. In both preclinical and clinical studies, psychostimulants including methamphetamine, MDMA, cocaine, and nicotine, produce BBB dysfunction through alterations in tight junction protein expression and conformation, increased glial activation, increased enzyme activation related to BBB cytoskeleton remodeling, and induction of neuroinflammatory pathways. These detrimental changes lead to increased permeability of the BBB and subsequent vulnerability of the brain to peripheral toxins. In fact, abuse of these psychostimulants, notably methamphetamine and cocaine, has been shown to increase the invasion of peripheral bacteria and viruses into the brain. Much work in this field has focused on the co-morbidity of psychostimulant abuse and human immunodeficiency virus (HIV) infection. As psychostimulants alter BBB permeability, it is likely that this BBB dysfunction results in increased penetration of the HIV virus into the brain thus increasing the risk of and severity of neuro AIDS. This review will provide an overview of the specific changes in components within the BBB associated with psychostimulant abuse as well as the implications of these changes in exacerbating the neuropathology associated with psychostimulant drugs and HIV co-morbidity.

Citing Articles

Something to talk about; crosstalk disruption at the neurovascular unit during HIV infection of the CNS.

Galpayage Dona K, Benmassaoud M, Gipson C, McLaughlin J, Ramirez S, Andrews A NeuroImmune Pharm Ther. 2025; 3(2):97-111.

PMID: 39958876 PMC: 11823645. DOI: 10.1515/nipt-2024-0003.


Therapeutic targeting of neuroinflammation in methamphetamine use disorder.

Jeffery N, Mock P, Yang K, Tham C, Israf D, Li H Future Med Chem. 2024; 17(2):237-257.

PMID: 39727147 PMC: 11749361. DOI: 10.1080/17568919.2024.2447226.


The impacts of tobacco and nicotine on HIV-1 infection, inflammation, and the blood-brain barrier in the central nervous system.

Keane A, Swartz T Front Pharmacol. 2024; 15:1477845.

PMID: 39529883 PMC: 11550980. DOI: 10.3389/fphar.2024.1477845.


How life events may confer vulnerability to addiction: the role of epigenetics.

Liu S, Harris A, Gewirtz J Front Mol Neurosci. 2024; 17:1462769.

PMID: 39359689 PMC: 11446245. DOI: 10.3389/fnmol.2024.1462769.


Unraveling the Role of the Blood-Brain Barrier in the Pathophysiology of Depression: Recent Advances and Future Perspectives.

Varghese S, Patel S, Nandan A, Jose A, Ghosh S, Sah R Mol Neurobiol. 2024; 61(12):10398-10447.

PMID: 38730081 DOI: 10.1007/s12035-024-04205-5.


References
1.
Paulson J, Yang T, Selvaraj P, Mdzinarishvili A, Van der Schyf C, Klein J . Nicotine exacerbates brain edema during in vitro and in vivo focal ischemic conditions. J Pharmacol Exp Ther. 2009; 332(2):371-9. PMC: 2812118. DOI: 10.1124/jpet.109.157776. View

2.
An S, Groves M, Gray F, Scaravilli F . Early entry and widespread cellular involvement of HIV-1 DNA in brains of HIV-1 positive asymptomatic individuals. J Neuropathol Exp Neurol. 1999; 58(11):1156-62. DOI: 10.1097/00005072-199911000-00005. View

3.
Conant K, St Hillaire C, Anderson C, Galey D, Wang J, Nath A . Human immunodeficiency virus type 1 Tat and methamphetamine affect the release and activation of matrix-degrading proteinases. J Neurovirol. 2004; 10(1):21-8. DOI: 10.1080/13550280490261699. View

4.
Kuhn D, Francescutti-Verbeem D, Thomas D . Dopamine quinones activate microglia and induce a neurotoxic gene expression profile: relationship to methamphetamine-induced nerve ending damage. Ann N Y Acad Sci. 2006; 1074:31-41. DOI: 10.1196/annals.1369.003. View

5.
Nath A, Haughey N, Jones M, Anderson C, Bell J, Geiger J . Synergistic neurotoxicity by human immunodeficiency virus proteins Tat and gp120: protection by memantine. Ann Neurol. 2000; 47(2):186-94. View